Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.
BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening,...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| 格式: | Journal article |
| 语言: | English |
| 出版: |
Public Library of Science
2008
|
| _version_ | 1826302532406738944 |
|---|---|
| author | Stevens, W Kamali, A Karita, E Anzala, O Sanders, E Jaoko, W Kaleebu, P Mulenga, J Dally, L Fast, P Gilmour, J Farah, B Birungi, J Hughes, P Manigart, O Stevens, G Yates, S Thomson, H von Lieven, A Krebs, M Price, M Stoll-Johnson, L Ketter, N |
| author_facet | Stevens, W Kamali, A Karita, E Anzala, O Sanders, E Jaoko, W Kaleebu, P Mulenga, J Dally, L Fast, P Gilmour, J Farah, B Birungi, J Hughes, P Manigart, O Stevens, G Yates, S Thomson, H von Lieven, A Krebs, M Price, M Stoll-Johnson, L Ketter, N |
| author_sort | Stevens, W |
| collection | OXFORD |
| description | BACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18-60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons. |
| first_indexed | 2024-03-07T05:48:59Z |
| format | Journal article |
| id | oxford-uuid:e833460d-96f3-43ec-9c7e-93da3ca8e3fd |
| institution | University of Oxford |
| language | English |
| last_indexed | 2024-03-07T05:48:59Z |
| publishDate | 2008 |
| publisher | Public Library of Science |
| record_format | dspace |
| spelling | oxford-uuid:e833460d-96f3-43ec-9c7e-93da3ca8e3fd2022-03-27T10:44:51ZBaseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials.Journal articlehttp://purl.org/coar/resource_type/c_dcae04bcuuid:e833460d-96f3-43ec-9c7e-93da3ca8e3fdEnglishSymplectic Elements at OxfordPublic Library of Science2008Stevens, WKamali, AKarita, EAnzala, OSanders, EJaoko, WKaleebu, PMulenga, JDally, LFast, PGilmour, JFarah, BBirungi, JHughes, PManigart, OStevens, GYates, SThomson, Hvon Lieven, AKrebs, MPrice, MStoll-Johnson, LKetter, NBACKGROUND: An understanding of the health of potential volunteers in Africa is essential for the safe and efficient conduct of clinical trials, particularly for trials of preventive technologies such as vaccines that enroll healthy individuals. Clinical safety laboratory values used for screening, enrolment and follow-up of African clinical trial volunteers have largely been based on values derived from industrialized countries in Europe and North America. This report describes baseline morbidity during recruitment for a multi-center, African laboratory reference intervals study. METHODS: Asymptomatic persons, aged 18-60 years, were invited to participate in a cross-sectional study at seven sites (Kigali, Rwanda; Masaka and Entebbe, Uganda; Kangemi, Kenyatta National Hospital and Kilifi, Kenya; and Lusaka, Zambia). Gender equivalency was by design. Individuals who were acutely ill, pregnant, menstruating, or had significant clinical findings were not enrolled. Each volunteer provided blood for hematology, immunology, and biochemistry parameters and urine for urinalysis. Enrolled volunteers were excluded if found to be positive for HIV, syphilis or Hepatitis B and C. Laboratory assays were conducted under Good Clinical Laboratory Practices (GCLP). RESULTS AND CONCLUSIONS: Of the 2990 volunteers who were screened, 2387 (80%) were enrolled, and 2107 (71%) were included in the analysis (52% men, 48% women). Major reasons for screening out volunteers included abnormal findings on physical examination (228/603, 38%), significant medical history (76, 13%) and inability to complete the informed consent process (73, 13%). Once enrolled, principle reasons for exclusion from analysis included detection of Hepatitis B surface antigen (106/280, 38%) and antibodies against Hepatitis C (95, 34%). This is the first large scale, multi-site study conducted to the standards of GCLP to describe African laboratory reference intervals applicable to potential volunteers in clinical trials. Approximately one-third of all potential volunteers screened were not eligible for analysis; the majority were excluded for medical reasons. |
| spellingShingle | Stevens, W Kamali, A Karita, E Anzala, O Sanders, E Jaoko, W Kaleebu, P Mulenga, J Dally, L Fast, P Gilmour, J Farah, B Birungi, J Hughes, P Manigart, O Stevens, G Yates, S Thomson, H von Lieven, A Krebs, M Price, M Stoll-Johnson, L Ketter, N Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title | Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title_full | Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title_fullStr | Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title_full_unstemmed | Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title_short | Baseline morbidity in 2,990 adult African volunteers recruited to characterize laboratory reference intervals for future HIV vaccine clinical trials. |
| title_sort | baseline morbidity in 2 990 adult african volunteers recruited to characterize laboratory reference intervals for future hiv vaccine clinical trials |
| work_keys_str_mv | AT stevensw baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT kamalia baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT karitae baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT anzalao baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT sanderse baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT jaokow baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT kaleebup baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT mulengaj baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT dallyl baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT fastp baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT gilmourj baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT farahb baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT birungij baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT hughesp baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT manigarto baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT stevensg baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT yatess baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT thomsonh baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT vonlievena baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT krebsm baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT pricem baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT stolljohnsonl baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials AT kettern baselinemorbidityin2990adultafricanvolunteersrecruitedtocharacterizelaboratoryreferenceintervalsforfuturehivvaccineclinicaltrials |